CD274 and neoplasm: In the in vivo xenograft model, tumor volumes treated with a combination of ceritinib and a PD-L1 inhibitor (91.9%) are significantly smaller than those treated with ceritinib (84.9%) or PD-L1 (20.0%) alone (70).